ArticleDiabetology & metabolic syndrome2025
IL-37 inhibited inflammation to improve gestational diabetes mellitus through the GSK3/NF-κB pathway.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Study on the Antidepressant Effect and Mechanism of Water Extract of Semiliquidambar cathayensis (WESC) Based on the GSK3β/NF-κB Signaling Pathway.Chemistry & biodiversity · 2026Article
- MaR1 and NGF combine to inhibit autophagy through the GSK-3β/β-catenin pathway to promote sciatic nerve repair.Journal of translational medicine · 2026Article
- Metabolic biomarkers in early detection of gestational diabetes mellitus: a prospective diagnostic accuracy study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of IL-37 in gestational diabetes mellitus (GDM) and its potential mechanisms.
methodsA GDM mouse model was constructed with a high-fat diet (HFD). The effects of IL-37 on glucose metabolism, insulin sensitivity, insulin resistance, and placental inflammation were examined using glucose and insulin tolerance tests, ELISA, western blot, HE staining, immunohistochemistry, immunofluorescence, and RT-qPCR. To further investigate the regulatory role of IL-37 in the GSK3/NF-κB pathway, experiments were repeated with the inclusion of DIF-3, a well-known activator of GSK3.
resultsThe results indicated that the expression of IL-37 was decreased in mice with GDM. IL-37 overexpression could reduce placental inflammation, promote M2 polarization in macrophages, and decrease the mRNA levels of inflammation factors. In addition, the overexpression of IL-37 may improve abnormal glucose metabolism, enhance insulin sensitivity, and alleviate insulin resistance. Mechanistic studies have demonstrated that the anti-inflammatory and pro-glucose metabolism effects of IL-37 in GDM were reversed by the GSK activator DIF-3. After treatment with DIF-3, mice in the IL-37-treated group exhibited increased expression of GSK3 and p-NF-κB protein, along with decreased expression of IRS-1, p-Akt, and GLUT4 protein. These results consistently indicated that IL-37 may suppress inflammation to ameliorate GDM through the modulation of the GSK3/NF-κB pathway.
conclusionIL-37 alleviated GDM by downregulating the activity of GSK-3/NF-κB. This modulation subsequently reduced inflammatory markers and improved insulin resistance.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.